ARCHIVES

Xeloda-Eloxatin Study Updated; Phase III Trial Interim Analysis

This article is from The Cancer Letter archive.

Vol. 25 No. 12 | December 27, 2002

Download PDF Visit The Full Archive

Related Articles

FDA Approves Votrient For Renal Cell Carcinoma

October 23, 2009

ASCO 2012: Michael Link’s Presidential Address, and the 2012 Award Winners

June 8, 2012

In Brief: Three Scientists Share Nobel Prize For Work In Genetics; Clinton Forms Bioethics Panel

October 13, 1995

NCAB To Seek Changes In Cancer Act Renewal, Budget Improvements

November 20, 1987

NIH Priority To Pay 4,000 Grants, Send Summary Statements

February 2, 1996

FDA Codifies Rules For Expanded Access, Charging For Drugs In Clinical Trials.

December 22, 2006